Topic: How To Invest

Power Growth Investor Hotline – Friday, August 26, 2022

Article Excerpt

ALCON INC., $66.74, is a buy. The company (symbol ALC in New York) is the world’s biggest eye-care company. Specifically, it’s the leader in ocular surgical supplies and No. 2 in contact lenses. Alcon has just agreed to buy Aerie Pharmaceuticals, symbol AERI on Nasdaq, for $770 million. Through the transaction, Alcon will acquire Aerie’s glaucoma and ocular hypertension drugs Rhopressa and Rocklatan. Apart from adding revenue from these two products, Aerie also brings AR-15512, a late-stage candidate for dry eye disease. On top of that drug prospect, the company has several other clinical and preclinical ophthalmic candidates in its pipeline. Overall, the deal complements Alcon’s recent expansion into the ophthalmic pharmaceutical eye drop space, including acquisitions of the exclusive U.S. commercialization rights to Simbrinza from Novartis in April 2021 and of Eysuvis and Inveltys from Kala Pharmaceuticals, Inc. in May 2022. Meanwhile, Alcon gives you two exciting ways to profit. First, it offers you exposure to rapidly expanding, worldwide demand for its contact…